Navigation Links
Organovo Announces Relocation and Commencement of Operations at Larger Facility
Date:7/17/2012

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today announced a facility relocation and expansion.  Organovo has moved its headquarters to a new 15,539 sq ft facility in San Diego, California. The facility consists of mixed lab and office space and features a clean room space nearly four times larger than Organovo's previous facility.  Clean room facilities are required for protection of the functional human tissues created by Organovo's innovative 3D bioprinting process.

The space is located in the Portola development in the Sorrento Mesa area of San Diego. Alexandria Real Estate is the property owner and manager through its regional LLC.  Cushman and Wakefield, LLC brokered the transaction, with Brent Jacobs and Greg Bisconti of the life sciences group representing Organovo. Organovo's previous headquarters facility consisted of 4,432 sq ft of mixed office and lab space. In the expanded facility, Organovo will continue its focus on developing bioprinting to create a broad array of functional 3D tissues that can recapitulate in vivo biology for human disease research, drug discovery and development, toxicology testing and, eventually, as therapies.

"Organovo's facility expansion provides a state-of-the-art space for our team to drive innovation with our research and development initiatives and supports partnering activities with our bioprinting technologies," commented Keith Murphy, chairman and chief executive officer of Organovo.  "We now have the space to expand our expertise into additional areas of research and development and to expand our bioprinting capacity with up to four NovoGen MMX Bioprinters in regular operation. The new facility provides essential resources for Organovo to advance the development of new bioprinter technologies, 3D
'/>"/>

SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
2. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
3. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
4. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
5. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
6. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
7. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
8. Inclinix-PMG Holdings, Inc. Announces Executive Management Changes
9. MetaStat, Inc. Announces Allowance of Patent Claims
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... -- Ryan & Maniskas, LLP that a class ... for the Northern District of California ... common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or the "Company") ... 15, 2015, inclusive (the "Class Period"). Avalanche shareholders ... for appointment as a lead plaintiff of the Class.  If ...
(Date:7/24/2015)... Origin Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), ... , today announced that the Company will report results ... 2015, before the market opens on Wednesday, August 5th, 2015. ... 5th, 2015, at 9:00 a.m. ET / 9:00 p.m. ... participate in the call, please dial the following numbers approximately ...
(Date:7/23/2015)... ... July 23, 2015 , ... The health and wellness of brain tumor ... of a brain tumor diagnosis. The American Brain Tumor Association presents interactive sessions that ... and Family Conference, July 24-25 in Chicago. , “We have understood for a ...
(Date:7/23/2015)... ... July 23, 2015 , ... The Pittcon 2016 Program ... S. Mosher Professor of Chemistry and Professor, by courtesy, of Applied Physics at Stanford ... Detection in Solids Led to Super-Resolution Nanoscopy in Cells and Beyond” , Dr. ...
Breaking Biology Technology:Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 2The 2014 Nobel Prize in Chemistry Recipient W. E. Moerner, to Deliver Wallace H. Coulter Lecture at Pittcon 2016 3
... Company to Hold a Conference Call Tomorrow (Tuesday) at 8:30 am ... ... September 10 XTL,Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: XTL; ... of Bicifadine - a serotonin,and norepinephrine reuptake inhibitor (SNRI) - for ...
... LONDON, Sept. 7 Chiltern, a leading global ... Richard Schulz,Chiltern,s Country Manager for the Czech Republic, ... The award ceremony was held in,London,s historic Gibson ... peers by a panel of judges who,reviewed his ...
... On Thursday, October,18, 2007, Wyeth (NYSE: WYE ) ... Company will hold a one-hour conference call with,research analysts ... Interested,investors and others may listen to the call live ... may be accessed by visiting our website,at http://www.wyeth.com ...
Cached Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. ... human interface solutions, today announced that Huawei has ... touchscreen solution for its stylish smartwatch. Huawei chose ... proven reliability, low power and highly responsive human ... finger. Huawei designers also required a classic round ...
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Looking into the brain is yielding vital clues to ... being presented today at the Seventh International Conference on ... held at 12:15 p.m., Thursday, June 7, have helped ... treatment of the disease. , The first study, presented ...
... crops may contribute to increased productivity in sustainable agriculture, ... 8 issue of the journal Science. The study ... field experiments all over the world, involving corn and ... insecticidal properties. The research was conducted by scientists ...
... In a way, nanotubes are nature’s smallest candles. , These ... so small that it takes about 100,000 laid side-by-side to ... last five years, scientists have discovered that some individual nanotubes ... in light. Some glow brightly. Others glow dimly. Some glow ...
Cached Biology News:Brain holds clues to bipolar disorder 2New study finds genetically engineered crops could play a role in sustainable agriculture 2Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 9(S)-HODE by ... the lipoxygenation of linoleic acid in both plants ... plaques, as an esterified component of membrane phospholipids ...
... 9(S)-HODE-d4 contains 4 deuterium atoms at the ... intended for use as an internal standard for ... spectrometry. 9(S)-HODE is produced by the lipoxygenation of ... has been detected in atherosclerotic plaques, as an ...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: